News

Moderna, FDA and Covid

FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.
FDA Fully Approves Moderna’s COVID Vaccine for Some Young Kids
The move makes Moderna’s vaccine, called Spikevax, the first COVID shot for kids in the U.S. to be fully approved, rather than used under emergency authorization, STAT News reported. The vaccine can now to be given to children ages 6 months through 11 years,
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / Moderna,
Moderna gets full US approval for COVID shot in at-risk children 6 months and older
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, the company said on Thursday.
FDA gives full approval to Moderna COVID shot for at-risk kids
The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is no longer administered under an emergency authorization.
FDA approves Moderna's COVID vaccine for children as young as 6 months old
Younger children will now have access to a COVID-19 vaccine — but only if they're considered at higher risk. The U.S. Food and Drug Administration approved "Spikevax," Moderna's vaccine for children aged 6 months to 11 years old.
FDA Approves New Covid Vaccine For Kids With Selective Eligibility
FDA grants full approval to Moderna's COVID-19 vaccine for children aged 6 months to 11 years with medical vulnerabilities, marking a shift from emergency use to selective eligibility.
Moderna wins full FDA approval for COVID shot in children
Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher risk. Read more here.
CNN2y
FDA approves Pfizer’s RSV vaccine for older adults - CNN
The US Food and Drug Administration on Wednesday approved Pfizer’s RSV vaccine for older adults, the second such shot approved for the common virus.
USA Today1y
Moderna wins FDA approval of RSV vaccine - USA TODAY
Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older.
Reuters8mon
US FDA approves Pfizer's RSV vaccine for adults at increased risk of ...
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk ...
The American Journal of Managed Care8mon
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abysvo, for adults aged 18 to 59 years who are at increased risk for the disease. | Image credit: Peter Hansen - stock ...
STAT25d
FDA approves Moderna RSV vaccine use for people aged 18 to 59 - STAT
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
U.S. News & World Report29d
US FDA Approves Expanded Use of Moderna's RSV Vaccine for At-Risk Adults
(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk ...
ABC News29d
FDA expands approval of Moderna's RSV vaccine to some adults under age ...
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.
PharmTech8mon
FDA Approves RSV Vaccine
Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...
UPI1mon
FDA approves Novavax's COVID-19 vaccine with limitations - UPI
The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.
Hosted on MSN29d
US FDA approves expanded use of Moderna's RSV vaccine for at-risk ... - MSN
(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk ...